ctDNA-guided treatment for early rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial is for people with early-stage rectal cancer. It uses a simple blood test to look for cancer DNA (ctDNA) to guide treatment decisions, helping avoid unnecessary treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that is a type called adenocarcinoma.
- You haven't had treatment for this cancer before, unless you're in a special group (Cohort B) that has already had chemotherapy and radiation.
- Your cancer has not spread to other parts of your body.
- You are 18 years or older.
- You are willing to sign a consent form and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
This study tests a “total neoadjuvant” approach—chemotherapy first, then radiation—using adaptive (tailored) radiation planning for people with locally advanced rectal cancer. It may help improve tumor control while adjusting the radiation based on how your cancer and anatomy respond.
This study looks at how well rectal cancer responds to chemotherapy and radiation before surgery. It uses a genetic test on tumor tissue to predict whether the treatment will work for you.
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
This trial uses a personalized blood test (ctDNA-MRD) to see how well neoadjuvant therapy works for rectal cancer. If you have stage II or III rectal cancer that can be surgically removed, this study might help guide your treatment.
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.